A partnership between Chinese company CanSino Biologics and Dalhousie University in Nova Scotia to develop a vaccine against COVID-19 has been abandoned.
–
The National Research Council of Canada (NRC) announced Thursday that CanSino’s vaccine intended for phase one clinical trials has not been approved by Chinese customs for shipment to Canada.
Due to this delay, the CNRC believes that the opportunity to conduct clinical trials is now over.
The CNRC says the Canadian Center for Vaccinology at Dalhousie University was ready to start clinical trials as early as June, when Health Canada approved CanSino’s project.
The Canadian Center for Vaccinology in Halifax was one of many laboratories in Canada and the United States whose work in 2014 resulted in the development of an Ebola vaccine for use in West Africa .
The CNRC said Thursday that it will focus on other partners and other priorities to fight COVID-19.
–
